Allostery and Biased Agonism at Class B G Protein-Coupled Receptors
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As far as GIP is concerned, after binding its receptor on beta cells, GIP transduces its biological effects by increasing in cAMP and intracytoplasmic Ca2+ levels, in addition to the activation of PI3K, AKT, PKA, p38 MAP kinases and phospholipase A2 [41].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [41]
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Ballesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Molecular signatures of G-protein-coupled receptors
Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., & Babu, M. M. (2013) · Nature · doi:10.1038/nature11896 · Cited by 1,497
Vaughan, J., Donaldson, C., Bittencourt, J., Perrin, M. H., Lewis, K., Sutton, S., Chan, R., Turnbull, A. V., Lovejoy, D., Rivier, C., et al. (1995) · Nature · doi:10.1038/378287a0 · Cited by 1,479
CRF and CRF receptors: role in stress responsivity and other behaviors
Bale, T. L., & Vale, W. W. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121410 · Cited by 1,270
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., & Morikawa, K. (2000) · Nature · doi:10.1038/35039564 · Cited by 1,249
Differential signal transduction by five splice variants of the PACAP receptor
Spongier, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburgt, P. H., & Journot, L. (1993) · Nature · doi:10.1038/365170a0 · Cited by 1,182
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K. C., Hashimoto, H., Galas, L., et al. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001370 · Cited by 1,058
Lewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925
Research works printed but not linked: 7
- 10.1124/pr.114.009464 · DOI
- 10.3109/10606820213681 · doi:10.3109/10606820213681 · Paper page
- Yamamoto Y., 2006, Cell Mol. Biol. (Noisy-le-grand), 52, 25
- 10.1124/mol.112.079319 · DOI
- Frohman L. A., 2002, Minerva Endocrinol., 27, 277
- 10.1210/mend.13.12.0391 · doi:10.1210/mend.13.12.0391 · Paper page
- 10.1210/jcem.85.5.6590 · doi:10.1210/jcem.85.5.6590 · Paper page
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
Self-citationG protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
Lu, S., He, X., Yang, Z., Chai, Z., Zhou, S., Wang, J., Rehman, A. U., Ni, D., Pu, J., Sun, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25020-9 · Cited by 223
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Zhang, X., Belousoff, M. J., Zhao, P., Kooistra, A. J., Truong, T. T., Ang, S. Y., Underwood, C. R., Egebjerg, T., Šenel, P., Stewart, G. D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.020 · Cited by 222
Self-citationStructural basis of G s and G i recognition by the human glucagon receptor
Qiao, A., Han, S., Li, X., Li, Z., Zhao, P., Dai, A., Chang, R., Tai, L., Tan, Q., Chu, X., et al. (2020) · Science · doi:10.1126/science.aaz5346 · Cited by 156
Self-citationZhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Tan, L., Yan, W., McCorvy, J. D., & Cheng, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00435 · Cited by 140
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions
Lu, S., & Zhang, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01844 · Cited by 158
Park, J., Langmead, C. J., & Riddy, D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00075 · Cited by 143
Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy
Furness, S. G. B., Liang, Y.-L., Nowell, C. J., Halls, M. L., Wookey, P. J., Dal Maso, E., Inoue, A., Christopoulos, A., Wootten, D., & Sexton, P. M. (2016) · Cell · doi:10.1016/j.cell.2016.09.021 · Cited by 134
Self-citationStructural Basis for Regulation of GPR56/ADGRG1 by Its Alternatively Spliced Extracellular Domains
Salzman, G. S., Ackerman, S. D., Ding, C., Koide, A., Leon, K., Luo, R., Stoveken, H. M., Fernandez, C. G., Tall, G. G., Piao, X., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.08.022 · Cited by 128
Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation
Liang, Y.-L., Belousoff, M. J., Zhao, P., Koole, C., Fletcher, M. M., Truong, T. T., Julita, V., Christopoulos, G., Xu, H. E., Zhang, Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.012 · Cited by 123
Self-citationSterically Shielded, Stabilized Nitrile Imine for Rapid Bioorthogonal Protein Labeling in Live Cells
An, P., Lewandowski, T. M., Erbay, T. G., Liu, P., & Lin, Q. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b00126 · Cited by 116
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“Virtually all GLP-1 ligands that have been assessed appropriately exhibit biased agonism relative to the principal endogenous GLP-1 peptide [GLP-1(7-36) (NH2)] (Koole et al., 2010; Graaf et al., 2016; Wootten et al., 2017).”
Self-citationDynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation
Deganutti, G., Liang, Y.-L., Zhang, X., Khoshouei, M., Clydesdale, L., Belousoff, M. J., Venugopal, H., Truong, T. T., Glukhova, A., Keller, A. N., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27760-0 · Cited by 90
Self-citationSalzman, G., Zhang, S., Gupta, A., Koide, A., Koide, S., & Araç, D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708810114 · Cited by 88
Allosteric modulation of G protein-coupled receptor signaling
Shen, S., Zhao, C. S., Wu, C., Sun, S., Li, Z., Yan, W. X., & Shao, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137604 · Cited by 87
Tail engagement of arrestin at the glucagon receptor
Chen, K., Zhang, C., Lin, S., Yan, X., Cai, H., Yi, C., Ma, L., Chu, X., Liu, Y., Zhu, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06420-x · Cited by 88
Endocrinology and the brain: corticotropin-releasing hormone signaling
Inda, C., Armando, N. G., Claro, P. A. D. S., & Silberstein, S. (2017) · Endocrine Connections · doi:10.1530/ec-17-0111 · Cited by 89
Allosteric coupling and biased agonism in G protein‐coupled receptors
Bock, A., & Bermudez, M. (2021) · The FEBS Journal · doi:10.1111/febs.15783 · Cited by 76
New Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 77
Self-citationPAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Kenakin, T., & Strachan, R. T. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.05.001 · Cited by 74
Structure and dynamics of the active Gs-coupled human secretin receptor
Dong, M., Deganutti, G., Piper, S. J., Liang, Y.-L., Khoshouei, M., Belousoff, M. J., Harikumar, K. G., Reynolds, C. A., Glukhova, A., Furness, S. G. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17791-4 · Cited by 56
Self-citationSuperfast Tetrazole–BCN Cycloaddition Reaction for Bioorthogonal Protein Labeling on Live Cells
Kumar, G. S., Racioppi, S., Zurek, E., & Lin, Q. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c10354 · Cited by 59
Negative allosteric modulation of the glucagon receptor by RAMP2
Kumar, K. K., O’Brien, E. S., Habrian, C. H., Latorraca, N. R., Wang, H., Tuneew, I., Montabana, E. A., Marqusee, S., Hilger, D., Isacoff, E. Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.028 · Cited by 60
Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism
Lei, S., Clydesdale, L., Dai, A., Cai, X., Feng, Y., Yang, D., Liang, Y.-L., Koole, C., Zhao, P., Coudrat, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003278 · Cited by 60
“However, optimally exploiting this property requires detailed mechanistic understanding of the drivers of bias (4).”
BackgroundSelf-citationFluorescent probes for G-protein-coupled receptor drug discovery
Iliopoulos‐Tsoutsouvas, C., Kulkarni, R., Makriyannis, A., & Nikas, S. P. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1518975 · Cited by 58
Yuliantie, E., Darbalaei, S., Dai, A., Zhao, P., Yang, D., Sexton, P. M., Wang, M.-W., & Wootten, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114001 · Cited by 53
Self-citationSeidel, L., Zarzycka, B. A., Zaidi, S. A., Katritch, V., & Coin, I. (2017) · eLife · doi:10.7554/elife.27711 · Cited by 58
“G-protein-coupled receptors (GPCRs) of class B comprise a family of 15 transmembrane receptors that respond to endocrine factors and regulate vital functions in mammals, including glucose and calcium homeostasis, pain transmission and gastrointestinal regulation (Bortolato et al., 2014; Wootten et al., 2017; Culhane e…”
Lu, J., Piper, S. J., Zhao, P., Miller, L. J., Wootten, D. L., & Sexton, P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158069 · Cited by 53
Self-citationPeptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 42
“Consequently, PF-06882961 is speculated to mirror native GLP-1 more closely by showing partial agonistic activity at recruiting beta-arrestin as well, but hitherto the augmentation of cAMP by the canonical pathway is sufficient to stimulate insulin secretion [45].”
BackgroundThe Molecular Control of Calcitonin Receptor Signaling
Maso, E. D., Glukhova, A., Zhu, Y., García‐Nafría, J., Tate, C. G., Atanasio, S., Reynolds, C. A., Ramírez-Aportela, E., Carazo, J. M., Hick, C. A., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00056 · Cited by 48
Self-citationIncretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Wootten, D. L., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Furness, S. G. B., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.015 · Cited by 45
“ECL2 plays an important role in this activation process [23,30,63] and mutations within this domain in the GLP-1R result in impaired cAMP production and iCa with less dramatic effects on pERK1/2 [30,31,65].”
BackgroundMethodInfluentialSelf-citationSeeking (and Finding) Biased Ligands of the Kappa Opioid Receptor
Bohn, L., & Aubé, J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00224 · Cited by 43
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide
Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Zhong, L., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 39
“GPCRs can be divided into subclasses based on sequence homology and evolution, and among these the B1 class encompasses receptors for many important peptide hormones (1, 2).”
BackgroundSelf-citationStructural Basis for Allosteric Modulation of Class B G Protein–Coupled Receptors
Wootten, D. L., & Miller, L. J. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023301 · Cited by 42
“Allosteric modulators of receptors are ligands that bind anywhere other than the site of receptor interaction with the natural orthosteric ligands (9; 10).”
Self-citationZhao, L., Lin, J., Ji, S., Zhou, X. E., Mao, C., Shen, D., He, X., Xiao, P., Sun, J., Melcher, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33851-3 · Cited by 37
“Both DNGα11 and DNGαo are chimera and the N termini of DNGα11 and DNGαo were replaced with the N-terminus of Gαi1, which can bind to scFv16 34.”
BackgroundInfluentialEvaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 33
Self-citationModulating effects of RAMPs on signaling profiles of the glucagon receptor family
Shao, L., Chen, Y., Zhang, S., Zhang, Z., Cao, Y., Yang, D., & Wang, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.028 · Cited by 34
Highly biased agonism for GPCR ligands via nanobody tethering
Sachdev, S., Creemer, B. A., Gardella, T. J., & Cheloha, R. W. (2024) · Nature Communications · doi:10.1038/s41467-024-49068-5 · Cited by 33
“We fi nd preliminary evidence of a difference for receptor activation in trans in comparing PTH 1-34 and PTH 1-11 -Nb PTHR1 , which suggests this mechanism may be important for biased agonism, consistent with reports of GPCR assemblies facilitating biased agonism 44,50 .”
ResultMaso, E. D., Zhu, Y., Pham, V., Reynolds, C. A., Deganutti, G., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., Wang, M.-W., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.005 · Cited by 30
“Introduction Class B1 G protein-coupled receptors (GPCRs) are the targets for peptide hormones that play major roles in the development and maintenance of lymphatic and cardiovascular function, bone homeostasis, metabolic regulation, migraine, stress and anxiety [1].”
BackgroundSelf-citationAmylin Receptor: A Potential Therapeutic Target for Alzheimer’s Disease
Fu, W., Patel, A., Kimura, R., Soudy, R., & Jhamandas, J. H. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.06.003 · Cited by 28
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Ruan, X., Chen, T., Wang, X., & Li, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4964 · Cited by 27
“G proteins (encoded by the Gnas gene) are important signal transducing molecules in cells (49).”
Roehrkasse, A. M., Booe, J. M., Lee, S. M., Warner, M. L., & Pioszak, A. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005062 · Cited by 25
“Understanding how the three peptides bind the receptors is especially important considering the phenomenon of signaling bias in which different ligands stabilize distinct receptor conformations to yield different downstream signaling outcomes (23).”
BackgroundLiu, Y., Wang, Y., Zhang, Y., Zou, Y. F., Wei, G., Ding, F., & Sun, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01202 · Cited by 23
PAC1 Receptors: Shapeshifters in Motion
Liao, C., May, V., & Li, J. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1132-0 · Cited by 23
“Accordingly, using currently available data as templates (Hollenstein et al. 2014; de Graaf et al. 2017; Wootten et al. 2017), we have recently constructed the fulllength human PAC1null receptor variant for structural studies and performed microsecond-long molecular dynamic (MD) simulations to delineate PAC1 receptor…”
Redij, T., Chaudhari, R. R., Li, Z., Hua, X., & Li, Z. (2019) · ACS Omega · doi:10.1021/acsomega.8b03052 · Cited by 23
RAMPs regulate signalling bias and internalisation of the GIPRPreprint
Harris, M., Mackie, D. I., Pawlak, J. B., Carvalho, S., Truong, T. T., Safitri, D., Yeung, H. Y., Routledge, S. J., Harper, M. T., Al‐Zaid, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.08.436756 · Cited by 23
“After its release, it is rapidly broken down by dipeptidylpeptidase IV (DPPIV) 16 to GIP (3-42), a weak partial agonist.”
BackgroundMethodSelf-citationSpatiotemporal GPCR signaling illuminated by genetically encoded fluorescent biosensors
Kayser, C., Melkes, B., Derieux, C., & Böck, A. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102384 · Cited by 19
GPCR structure and function relationship: identification of a biased apelin receptor mutant
Ban, T. T., Li, X., Ma, X., Yang, H. L., Song, Y., Sun, Y., Shen, M. C., Li, N., Zhang, M.-Y., Ma, Y., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180740 · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“As far as GIP is concerned, after binding its receptor on beta cells, GIP transduces its biological effects by increasing in cAMP and intracytoplasmic Ca 2+ levels, in addition to the activation of PI3K, AKT, PKA, p38 MAP kinases and phospholipase A2 [41].”
BackgroundTemperature-Responsive Nano-Biomaterials from Genetically Encoded Farnesylated Disordered Proteins
Hossain, M. S., Zhang, Z., Ashok, S., Jenks, A. R., Lynch, C. J., Hougland, J. L., & Mozhdehi, D. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01162 · Cited by 17
Routledge, S. J., Simms, J., Clark, A., Yeung, H. Y., Wigglesworth, M. J., Dickerson, I. M., Kitchen, P., Ladds, G., & Poyner, D. R. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.183174 · Cited by 16
Li, B., Maruszko, K., Kim, S., Yang, M. Y., Vo, A.-D. P., & Goddard, W. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05996 · Cited by 15
Peeking at G-protein-coupled Receptors Through the Molecular Dynamics Keyhole
Deganutti, G., Moro, S., & Reynolds, C. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0393 · Cited by 17
Extracellular nucleotides enhance agonist potency at the parathyroid hormone 1 receptor
Kim, B. H., Pereverzev, A., Zhu, S., Tong, A. O. M., Dixon, S. J., & Chidiac, P. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.02.015 · Cited by 17
Redij, T., Ma, J., Li, Z., Hua, X., & Li, Z. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00254-4 · Cited by 16
The Intricacies of Renal Phosphate Reabsorption—An Overview
Walker, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094684 · Cited by 17
“…Rho guanine nucleotide exchange factors, and G i/o , which inhibits adenylyl The G γ subunit can couple to diverse transducer proteins, such as a wide array of G proteins, kinases, and arrestin proteins [130,131]. cyclase activity and interacts with and signals via β -arrestins [124,127–129].”
BackgroundLabel-free biosensor assay decodes the dynamics of Toll-like receptor signaling
Holze, J., Lauber, F., Soler, S., Kostenis, E., & Weindl, G. (2024) · Nature Communications · doi:10.1038/s41467-024-53770-9 · Cited by 13
Kim, B. H., Wang, F. I., Pereverzev, A., Chidiac, P., & Dixon, S. J. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00053 · Cited by 13
Structure, function and therapeutic potential of adhesion GPCRs
Araç, D., & Leon, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00002-7 · Cited by 15
Pham, V., Zhu, Y., Maso, E. D., Reynolds, C. A., Deganutti, G., Atanasio, S., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00010 · Cited by 14
Self-citationYu, Z., Cary, B. P., Kim, T. W., Nguyen, K. D., Gardella, T. J., & Gellman, S. H. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00595 · Cited by 12
Targeting G protein‐coupled receptors for heart failure treatment
Thai, B. S., Chia, L. Y., Nguyen, A. T. N., Qin, C. X., Ritchie, R. H., Hutchinson, D. S., Kompa, A. R., White, P. J., & May, L. T. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16099 · Cited by 12
“GLP-1 receptor activation results in insulin priming and insulin granule exocytosis in pancreatic β cells (Wootten et al., 2017).”
BackgroundLu, J. N., & Willars, G. B. (2019) · Biochemical Journal · doi:10.1042/bcj20180853 · Cited by 12
Rational development of a high-affinity secretin receptor antagonist
Dong, M., Harikumar, K. G., Raval, S. R., Milburn, J. E., Clark, C. E., Alcala‐Torano, R., Mobarec, J. C., Reynolds, C. A., Ghirlanda, G., Christopoulos, A., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113929 · Cited by 10
“Both of these applications are timely and important for class B G protein-coupled receptors (GPCRs), a family that has profound functional importance and includes many important therapeutic targets [1,2].”
BackgroundSelf-citationLeuthardt, A. S., Boyle, C. N., Raun, K., Lutz, T. A., John, L. M., & Foll, C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175912 · Cited by 12
Li, B., Yang, M. Y., Kim, S., & Goddard, W. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c08128 · Cited by 9
Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors
Liu, T., Naidoo, N. R., Agyemang, E., & Lamichhane, R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110466 · Cited by 9
Biased signaling in drug discovery and precision medicine
Ji, R., & Tao, Y. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108804 · Cited by 9
Darbalaei, S., Chang, R., Zhou, Q., Chen, Y., Dai, A., Wang, M., & Yang, D. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00962-y · Cited by 9
“However, each receptor variably couples to secondary proteins resulting in different physiological functions [20].”
BackgroundBiased Allosteric Modulation in GPCR Drug Discovery
Zhou, J.-C., Li, M., Long, A., & Kahsai, A. W. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_771 · Cited by 9
Cary, B. P., Hager, M. V., & Gellman, S. H. (2019) · ChemBioChem · doi:10.1002/cbic.201900300 · Cited by 9
Harikumar, K. G., Coudrat, T., Desai, A. J., Dong, M., Dengler, D. G., Furness, S. G. B., Christopoulos, A., Wootten, D. L., Sergienko, E. A., Sexton, P. M., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.789957 · Cited by 8
“org 10 augment physiological signaling that is not possible with full agonists acting at the same receptors (29), provide novel opportunities for disease intervention.”
BackgroundSelf-citationFunctional characterisation of G protein-coupled receptors
Uddin, R., Simms, J., & Poyner, D. R. (2018) · Methods · doi:10.1016/j.ymeth.2018.02.018 · Cited by 9
Core conformation of arrestin coupling to parathyroid hormone type 1 receptor
Zhai, X., Guo, J., Shen, Q., Chen, L.-N., Wang, G., Shen, D.-D., Zhang, C., Xu, X., Mao, C., Zhang, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72448-y · Cited by 7
Singh, K., Nawabjan, S. A., Zhang, L., El-Nezami, H. S., Annapureddy, R. R., & Chow, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114642 · Cited by 7
Redij, T., McKee, J. A., Do, P., Campbell, J. A., Ma, J., Li, Z., Miller, N., Srikanlaya, C., Zhang, D., Hua, X., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14039 · Cited by 7
“…of GLP- 1R PAMs as small molecule drugs could offer reduced side effects as a therapeutic benefit (Khoury et al., 2014; Pupo et al., 2016; Wootten et al., 2017) and has attracted considerable effort toward the early discovery of GLP- 1R PAMs worldwide (Chen et al., 2007; Teng et al.,…”
BackgroundLin, S., Tien, Y.-W., Ke, Y., Chang, Y.-C., Chang, H.-F., Ou, L.-C., Law, P., Xi, J.-H., Tao, P., Loh, H. H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105905 · Cited by 6
Ramos-Álvarez, I., Iordanskaia, T., Mantey, S. A., & Jensen, R. T. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.001033 · Cited by 6
Kang, S., Kim, N. H., & Yu, Y. G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.071 · Cited by 6
Fine-tuning receptor–G protein activation and signaling
Lebon, G. (2020) · Science · doi:10.1126/science.abc9291 · Cited by 6
Elisi, G. M., & Bottegoni, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108905 · Cited by 5
Negative allosteric modulation of the glucagon receptor by RAMP2Preprint
Kumar, K. K., O’Brien, E. S., Habrian, C. H., Latorraca, N. R., Wang, H., Tuneew, I., Montabana, E. A., Marqusee, S., Hilger, D., Isacoff, E. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.30.505955 · Cited by 5
Cancer-Associated Mutations Enhance The Sensitivity Of The Trupath Gα Q/11 SystemPreprint
Safitri, D., Harris, M., Pearce, A., Huang, X., Rosa, M., Barkan, K., Wills, E., Martí-Solano, M., Falk, M. D., & Ladds, G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.506210 · Cited by 5
“For example, activation of a number of class B1 GPCRs has been demonstrated to result in the mobilisation of (Ca)i from intracellular stores and that this is, at least in part, Gq/11-dependent (Clark et al., 2021; Drissi et al., 1998; Harris et al., 2021; Hinkle et al., 2005; Wootten et al., 2017).”
BackgroundInfluentialSystemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01870-x · Cited by 3
“An emerging and highly promising strategy involves developing multi-target agonists that also engage the glucagon-like insulinotropic polypeptide receptor (GIPR) and/or the glucagon receptor (GCGR) [14, 15].”
Is there a common allosteric binding site for G-protein coupled receptors?
Malik, F., & Li, Z. (2022) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-022-00454-5 · Cited by 3
“Allosteric ligands provide several potential benefits, including better subtype selectivity and more druggable binding sites [9, 10].”
BackgroundRising Stars: Molecular Mechanisms of Ligand Recognition and Functional Modulation of GPCRs
Han, S., Tan, Q., Lin, S., Chen, K., He, M., Zhao, Q., & Wu, B. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169674 · Cited by 2
Regulación del gen PEIG-1/GPRC5A por 12-O-tetradecanoilforbol-13-acetato
Mori, C. (2020) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/107365 · Cited by 2
An Industrial Perspective on Ligand Bias in GPCR Drug Discovery.
Farmer, J. P., Mason, J., Holliday, N., Briddon, S., & Stoddart, L. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110782
Atomic, structural and molecular insights into GPCR ligand binding and signalling
Nemec, K., Mészáros, B., Skiniotis, G., Blanchard, S. C., & Babu, M. M. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-026-01030-7 · Cited by 1
Structural studies and drug discovery of G protein-coupled receptors
Yang, Z., & Wu, B. (2018) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972018-00307 · Cited by 2
Amylin and amylin receptors in Alzheimer's disease
Fu, W., & Jhamandas, J. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00020-7 · Cited by 1
CRHR1 endocytosis: Spatiotemporal regulation of receptor signaling
Claro, P. A. D. S., Silbermins, M., Inda, C., & Silberstein, S. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.015 · Cited by 2
Metadata
- Authors
- Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M.
- Affiliations
- Monash University (AU)
- Mayo Clinic (US)
- Corresponding author
- Wootten, Denise
- Miller, Laurence J.
- Sexton, Patrick M.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-04-04
- Volume
- 117
- Issue
- 1
- Pages
- 111-138
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2331593504
- Cited by
- 112
- References
- 280
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 18 · 2021: 10 · 2020: 12 · 2019: 12 · 2018: 17 · 2017: 10 · 2016: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (1055134, 1061044, 1065410)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- class B G protein-coupled receptors, biased agonism, allosteric site, small molecule drug discovery, peptide hormones, osteoporosis, type 2 diabetes, obesity, drug development
- MeSH terms
- Allosteric Regulation, Structure-Activity Relationship, Dimerization, Receptors, G-Protein-Coupled
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.